Tests genetic-guided medication review by pharmacists for depression
Tests pharmacist medication review using gene test results in adults with depression.
Plain-language title generated from the registry record
Registry title: An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.
Key facts
- Where
- Pittsburgh, United StatesSee the site
Where in United States
- University of PittsburghPittsburgh, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Pittsburgh
- Trial code
- NCT07373470
- Record updated
- 14 September 2026
- Original description
The goal of this prospective, randomized clinical trial is to learn whether pharmacogenomic (PGx)-guided comprehensive medication management delivered by pharmacists in community pharmacies will improve antidepressant treatment outcomes.Read full original descriptionShow less
Genotype-guided Comprehensive Medication Management to Improve Depression Outcomes in Pennsylvania
The goal of this prospective, randomized clinical trial is to learn whether pharmacogenomic (PGx)-guided comprehensive medication management delivered by pharmacists in community pharmacies will improve antidepressant treatment outcomes.
The primary aim is to determine whether comprehensive medication management with review of PGx testing results improves depression symptoms, compared with usual care.
Participants 18 years of age or older who have undergone PGx testing (e.g. through an independent biobanking study (Pitt+Me Discovery) who require initiation or adjustment of antidepressant therapy will be randomly assigned to receive either PGx-guided comprehensive medication management or usual care. Those who receive usual care will receive their PGx results at the end of the study. Researchers will compare the groups to assess whether PGx-guided care provided in partnership with community pharmacists and prescribers results in better depression and medication outcomes.
Inclusion: At targeted community pharmacy for:; New prescription or change in dose/schedule of SSRI (citalopram, escitalopram, sertraline, paroxetine), OR; Concurrent SSRI (citalopram, escitalopram, sertraline, paroxetine) and new prescription/change in SNRI (desvenlafaxine, duloxetine, and venlafaxine) / bupropion; Depressive symptoms confirmed by PHQ8 assessment (>5 indicating at least mild depressive symptoms); UPMC patient (or able/willing to become one) and has UPMC provider (or able/willing to obtain one); Signed consent to join Pitt+Me Discovery biobanking research study; English-speaking.
Exclusion: Pitt+Me Discovery participant who has elected to not receive return of results, or who has already received results previously; Untreated sleep disorder (patient-reported); Inability to receive CMM at specific pharmacy/pharmacist; Comorbid diagnosis of schizophrenia (patient-reported).